Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tarsus Pharmaceuticals (TARS) EPS (Weighted Average and Diluted) (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.17 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 70.18% year-over-year to -$0.17; the TTM value through Dec 2025 reached -$1.59, up 48.21%, while the annual FY2025 figure was -$1.59, 48.21% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.17 in Q4 2025 per TARS's latest filing, up from -$0.3 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.47 in Q1 2021 and bottomed at -$1.28 in Q3 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.62, with a median of -$0.68 recorded in 2021.
  • Peak YoY movement for EPS (Weighted Average and Diluted): surged 163.51% in 2021, then plummeted 387.5% in 2023.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.72 in 2021, then soared by 36.11% to -$0.46 in 2022, then crashed by 176.09% to -$1.27 in 2023, then skyrocketed by 55.12% to -$0.57 in 2024, then surged by 70.18% to -$0.17 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$0.17 in Q4 2025, -$0.3 in Q3 2025, and -$0.48 in Q2 2025.